Kenvue rebounds after Trump Tylenol claims as analysts see limited legal risk
Kenvue shares rose more than 5% in premarket trading on Tuesday, staging a recovery from a record low hit the previous session after US President Donald Trump linked the company's popular pain relieve... ...